tbuckley/cabot-search huggingface dataset:
Translational Research in Cardiovascular Repair
Authors: Steven A.J. Chamuleau, Mira van der Naald, Andreu M. Climent, Adriaan O. Kraaijeveld, Kim E. Wever, Dirk J. Duncker, Francisco Fernández-Avilés, Roberto Bolli
Journal: Circulation Research (2018)

The international consortium TACTICS (Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes) has recently addressed key priorities in the field of cell-based therapy for cardiac repair, identifying the efficacy of translational research as one of the main challenges to ultimately improve the quality of life of patients with ischemic disease. Much of the controversy and confusion surrounding cardiac regenerative therapy stems from insufficient rigor in the conduct of preclinical studies, and there is an increasing recognition of a number of problems that undermine its quality that may contribute to translational failure. Here, we introduce well defined stages for preclinical research, and put forth proposals that should promote more rigorous preclinical work, in an effort to improve its quality and translatability. To augment the utility of preclinical research and its translation, it is necessary to (1) improve the quality of preclinical research, (2) promote collaborative efforts, and (3) enhance the sharing of knowledge and protocols. In particular, confirmatory (stage III) preclinical studies should be considered as a preamble to clinical studies and therefore must adhere to their standards of quality (including internal validity, standardization of protocols, and multicenter design). To increase transparency and minimize bias, these studies should be prospectively registered in an independent, open database. Ultimately, these recommendations should be implemented in the daily routine of investigators and in the policies of institutions, journals, and funding agencies.
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Authors: Mathias Granqvist, Malin Boremalm, Amyar Poorghobad, Anders Svenningsson, Jonatan Salzer, Thomas Frisell, Fredrik Piehl
Journal: JAMA Neurology (2018)

<h3>Importance</h3> Comparative real-world effectiveness studies of initial disease-modifying treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include rituximab are lacking. <h3>Objective</h3> To assess the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed RRMS compared with injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab. <h3>Design, Setting, and Patients</h3> This retrospective cohort study used prospectively collected data to examine specialized care of 2 Swedish county–based community samples of patients with RRMS. Patients with RRMS who received diagnoses from January 1, 2012, to October 31, 2015, who resided in Stockholm or Västerbotten Counties were identified from a Swedish multiple sclerosis registry. <h3>Main Outcomes and Measures</h3> All reasons for drug discontinuation of initial treatment choice (main outcome) and specific reasons for switching (secondary outcomes) were analyzed with multivariable Cox regression, including propensity scores. <h3>Results</h3> Among 494 patients (median [interquartile range] age, 34.4 [27.4-43.4] years; 158 men [32.0%]), 215 received an injectable DMT (43.5%); 86 (17.4%), dimethyl fumarate; 17 (3.4%), fingolimod; 50 (10.1%), natalizumab; 120 (24.3%), rituximab; and 6 (1.2%), other DMT. Regional preferences were pronounced, with 42 of 52 (81%) and 78 of 442 (18%) receiving rituximab in Västerbotten and Stockholm, respectively. The annual discontinuation rate for rituximab, injectable DMTs, dimethyl fumarate, fingolimod, and natalizumab were 0.03, 0.53, 0.32, 0.38, and 0.29, respectively. Continued disease activity was the main reason for discontinuation of injectable DMTs, dimethyl fumarate, and fingolimod; positive John Cunningham virus serology results were the main reason for discontinuation of natalizumab. Rate of clinical relapses and/or neuroradiologic disease activity were significantly lower for rituximab compared with injectable DMTs and dimethyl fumarate, with a tendency for lower relapse rates also compared with natalizumab and fingolimod. The annual discontinuation rate of initial treatment choice was significantly lower in Västerbotten compared with Stockholm (0.09 and 0.37, respectively). <h3>Conclusions and Relevance</h3> Rituximab was superior to all other DMT in terms of drug discontinuation and displayed better clinical efficacy compared with injectable DMTs and dimethyl fumarate with borderline significance compared with natalizumab and fingolimod. The county where rituximab constituted the main initial treatment choice displayed better outcomes in most measured variables. Collectively, our findings suggest that rituximab performs better than other commonly used DMTs in patients with newly diagnosed RRMS.
Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial
Authors: Hai-Dong Zhu, Jin-He Guo, Ming Huang, Jian-Song Ji, Hao Xu, Jian Lu, Hai-Liang Li, Wen-Hui Wang, Yu-Liang Li, Cai-Fang Ni, Hai-Bin Shi, En-Hua Xiao, Wei-Fu Lv, Jun-Hui Sun, Ke Xu, Guo-Hong Han, Lin-An Du, Wei-Xin Ren, Mao-Quan Li, Ai-Wu Mao, Hua Xiang, Kai-Xian Zhang, Jie Min, Guang-Yu Zhu, Chang Su, Li Chen, Gao-Jun Teng
Journal: Journal of Hepatology (2018)
Fissured tongue in patients with psoriasis
Authors: Bruna Lavinas Sayed Picciani, Thays Teixeira-Souza, Thiago Moreira Pessôa, Lívia Maria Santos Izahias, Jane Marcy Neffa Pinto, David Rubem Azulay, João Carlos Regazzi Avelleira, Sueli Carneiro, Eliane Pedra Dias
Journal: Journal of the American Academy of Dermatology (2018)
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
Authors: J. Caers, B. Paiva, E. Zamagni, X. Leleu, J. Bladé, S. Y. Kristinsson, C. Touzeau, N. Abildgaard, E. Terpos, R. Heusschen, E. Ocio, M. Delforge, O. Sezer, M. Beksac, H. Ludwig, G. Merlini, P. Moreau, S. Zweegman, M. Engelhardt, L. Rosiñol
Journal: Journal of Hematology & Oncology (2018)

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography–computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.
The impact of digital health technologies on tuberculosis treatment: a systematic review
Authors: Brian Kermu Ngwatu, Ntwali Placide Nsengiyumva, Olivia Oxlade, Benjamin Mappin-Kasirer, Nhat Linh Nguyen, Ernesto Jaramillo, Dennis Falzon, Kevin Schwartzman
Journal: European Respiratory Journal (2018)

Digital technologies are increasingly harnessed to support treatment of persons with tuberculosis (TB). Since in-person directly observed treatment (DOT) can be resource intensive and challenging to implement, these technologies may have the potential to improve adherence and clinical outcomes. We reviewed the effect of these technologies on TB treatment adherence and patient outcomes. We searched several bibliographical databases for studies reporting the effect of digital interventions, including short message service (SMS), video-observed therapy (VOT) and medication monitors (MMs), to support treatment for active TB. Only studies with a control group and which reported effect estimates were included. Four trials showed no statistically significant effect on treatment completion when SMS was added to standard care. Two observational studies of VOT reported comparable treatment completion rates when compared with in-person DOT. MMs increased the probability of cure (RR 2.3, 95% CI 1.6–3.4) in one observational study, and one trial reported a statistically significant reduction in missed treatment doses relative to standard care (adjusted means ratio 0.58, 95% CI 0.42–0.79). Evidence of the effect of digital technologies to improve TB care remains limited. More studies of better quality are needed to determine how such technologies can enhance programme performance.
Measurement of the fraction of exhaled breath temperature as a biomarker of asthma control in patients in northeastern Mexico
Authors: Cindy Elizabeth de Lira-Quezada, Sandra Nora Gonzalez-Diaz, Alfredo Arias Cruz, Barbara Elizondo Villarreal, Carlos Macouzet-Sanchez, Gabriela Galindo-Rodriguez, Rosalaura Virginia Villarreal-Gonzalez, Rosa Ivett Guzman-Avilan, Daniel Sanchez-Guerra, Emilio G. Soto-Zamora
Journal: Journal of Allergy and Clinical Immunology (2018)
Phase 1 dose escalation study of the folate receptor-targeted small molecule drug conjugate EC1456.
Authors: Wael A. Harb, Martin J. Edelman, Setsuko K. Chambers, Linda L. Garland, Alison Armour, Ding Wang, Glenwood D. Goss, Jasgit Sachdev
Journal: Journal of Clinical Oncology (2017)

2576 Background: The folate receptor (FR) is highly expressed in a variety of cancers including adenocarcinoma of the lung, but is expressed at low levels in most normal tissues, making it a potential target for therapeutic intervention. EC1456 is an FR-targeted small molecule drug conjugate (SMDC) consisting of folic acid chemically attached through a bio-releasable linker system to a potent microtubule inhibitor, tubulysin B hydrazide (TubBH). EC1456 binds to, and is endocytosed by the FR-expressing cancer cell to deliver TubBH. Following endocytosis, the FR recycles back to the membrane surface every 18-24 hours. Therefore alternative EC1456 schedules will be evaluated for safety, pharmacokinetics, and therapeutic benefit. Methods: Part A (dose escalation) is being evaluated in unselected patients (pts) with advanced solid tumors. 4 schedules (3-week cycle) are being evaluated: BIW (twice weekly); QW (once weekly); CWD (continuously weekly); QIW (four times a week). The primary objective of Part A is to determine the RP2 dose and schedule of EC1456. Part B (expansion) will confirm the MTD and RP2 dose and evaluate efficacy of EC1456 in 99m Tc-etarfolatide-selected NSCLC patients in up to three schedules. Results: 74 Part A pts are evaluable for toxicity. Median age is 68 (range: 26-88); 53 pts are female. Toxicities are primarily Grade (Gr) 1 and 2. Common treatment-related adverse events (TRAE) are gastrointestinal, fatigue, metabolic changes, alopecia, and headache. 5 Gr 3 DLTs have been observed: infusion reaction (4.5 mg/m 2 QW), headache (10.0 mg/m 2 QW), and abdominal pain (7.5 mg/m 2 BIW, 12.5 mg/m 2 QW and 10.0 mg/m 2 CWD). TRAEs are summarized in the table for each schedule. Durable stable disease of 12 wks or longer has been observed in 12 pts (6 BIW and 6 QW). Conclusions: All Part A EC1456 schedules have been well tolerated. RP2 dose for BIW is 6.0 mg/m 2 and QW is 12.5 mg/m 2 ; dose escalation is ongoing for CWD and QIW. Early signs of efficacy in an unselected pt population may be suggested by durable stable disease. Safety and efficacy evaluation in the 99m Tc-etarfolatide-selected NSCLC population (Part B) is ongoing. Clinical trial information: NCT01999738. [Table: see text]
Exhalation Delivery System with Fluticasone (EDS-FLU) Improves Health-Related Quality of Life (HRQoL) in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from NAVIGATE II
Authors: Shaila U. Gogate, John C. Messina, Jennifer L. Carothers, Per G. Djupesland, Ramy A. Mahmoud
Journal: Journal of Allergy and Clinical Immunology (2018)
Exome Sequencing Studies Identify Mutations in STAB2 As a Genetic Risk for Venous Thromboembolic Disease
Authors: Karl Desch, Ayse Bilge Ozel, Matthew Halvorsen, Alison L. Michels, Laura L Swystun, Lauren Mokry, Brent Richards, Marine Germain, David A. Tregouet, Pieter H. Reitsma, Clive Kearon, Jun Z Li, David B. Goldstein, David Lillicrap, David Ginsburg
Journal: Blood (2017)
Exploiting Advanced Hydrogel Technologies to Address Key Challenges in Regenerative Medicine
Authors: Daniel A. Foyt, Michael D. A. Norman, Tracy T. L. Yu, Eileen Gentleman
Journal: Advanced Healthcare Materials (2018)

Abstract Regenerative medicine aims to tackle a panoply of challenges from repairing focal damage to articular cartilage to preventing pathological tissue remodeling after myocardial infarction. Hydrogels are water‐swollen networks formed from synthetic or naturally derived polymers and are emerging as important tools to address these challenges. Recent advances in hydrogel chemistries are enabling researchers to create hydrogels that can act as 3D ex vivo tissue models, allowing them to explore fundamental questions in cell biology by replicating tissues' dynamic and nonlinear physical properties. Enabled by cutting edge techniques such as 3D bioprinting, cell‐laden hydrogels are also being developed with highly controlled tissue‐specific architectures, vasculature, and biological functions that together can direct tissue repair. Moreover, advanced in situ forming and acellular hydrogels are increasingly finding use as delivery vehicles for bioactive compounds and in mediating host cell response. Here, advances in the design and fabrication of hydrogels for regenerative medicine are reviewed. It is also addressed how controlled chemistries are allowing for precise engineering of spatial and time‐dependent properties in hydrogels with a look to how these materials will eventually translate to clinical applications.
Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets
Authors: Bradley H. Rosen, T. Idil Apak Evans, Shashanna R. Moll, Jaimie S. Gray, Bo Liang, Xingshen Sun, Yulong Zhang, Chandler W. Jensen-Cody, Anthony M. Swatek, Weihong Zhou, Nan He, Pavana G. Rotti, Scott R. Tyler, Nicholas W. Keiser, Preston J. Anderson, Leonard Brooks, Yalan Li, R. Marshall Pope, Maheen Rajput, Eric A. Hoffman, Kai Wang, J. Kirk Harris, Kalpaj R. Parekh, Katherine N. Gibson-Corley, John F. Engelhardt
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Classical interpretation of cystic fibrosis (CF) lung disease pathogenesis suggests that infection initiates disease progression, leading to an exuberant inflammatory response, excessive mucus, and ultimately bronchiectasis. Although symptomatic antibiotic treatment controls lung infections early in disease, lifelong bacterial residence typically ensues. Processes that control the establishment of persistent bacteria in the CF lung, and the contribution of noninfectious components to disease pathogenesis, are poorly understood.To evaluate whether continuous antibiotic therapy protects the CF lung from disease using a ferret model that rapidly acquires lethal bacterial lung infections in the absence of antibiotics.CFTR (cystic fibrosis transmembrane conductance regulator)-knockout ferrets were treated with three antibiotics from birth to several years of age and lung disease was followed by quantitative computed tomography, BAL, and histopathology. Lung disease was compared with CFTR-knockout ferrets treated symptomatically with antibiotics.Bronchiectasis was quantified from computed tomography images. BAL was evaluated for cellular differential and features of inflammatory cellular activation, bacteria, fungi, and quantitative proteomics. Semiquantitative histopathology was compared across experimental groups. We demonstrate that lifelong antibiotics can protect the CF ferret lung from infections for several years. Surprisingly, CF animals still developed hallmarks of structural bronchiectasis, neutrophil-mediated inflammation, and mucus accumulation, despite the lack of infection. Quantitative proteomics of BAL from CF and non-CF pairs demonstrated a mucoinflammatory signature in the CF lung dominated by Muc5B and neutrophil chemoattractants and products.These findings implicate mucoinflammatory processes in the CF lung as pathogenic in the absence of clinically apparent bacterial and fungal infections.
Abstract 16068: Polycythemia Vera is Associated With Increased Atrial Fibrillation Compared to the General Population: Results From the National Inpatient Sample Database
Authors: Parasuram Krishnamoorthy, Aditi Kalla, Akshaya Gopalakrishnan, Varun Mittal, Jalaj Garg, Nainesh C Patel, Janani Rangaswami, Vincent M Figueredo
Journal: Circulation (2016)

Introduction: Polycythemia vera (PV) is a myeloproliferative disorder characterized by a chronic inflammatory state, which is a known risk factor for cardiovascular disease. Currently, there is a p...
Challenges for Today’s Pediatric Physician-Scientists
Authors: Barbara J. Stoll, Heinrich Taegtmeyer
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Barriers to Implementation of the NIAID Guideline Among Primary Care Physicians and Allergists
Authors: Elissa Michele Abrams, Alexander Singer, Lianne Soller, Edmond S. Chan
Journal: Journal of Allergy and Clinical Immunology (2018)

The approach to peanut allergy prevention has shifted with publication of the Learning Early About Peanut (LEAP) trial and recently released NIAID guideline. Our objective was to determine whether current practice patterns at both the allergist and primary care level are in keeping with the LEAP recommendations and NIAID guideline. A 17-question survey was distributed in 2016 to Canadian allergists through the Canadian Society of Allergy and Clinical Immunology, pediatricians through the Canadian Pediatric Society, and a sample of practicing family physicians. There was variability in the definition of infants at high risk for peanut allergy and recommendations for age of introduction of allergenic solids. There was also variability in how often allergist evaluation was recommended for infants with egg allergy or severe eczema prior to peanut introduction, with allergists 9 times more likely to recommend pre-emptive peanut testing in infants with severe eczema prior to peanut introduction. The majority of family physicians (77.1%), pediatricians (91.4%) and allergists (89.1%) did not believe there was harm to introduction of solids between 4-6 months of age, or that breastfeeding rates would be affected with earlier solid introduction. Further education about the implications of LEAP is required. There are broad issues (such as the definition of a high risk infant) that require international consensus. Most primary care physicians and allergists do not believe there are harms to introduction of allergenic solids prior to 6 months of age, or that breastfeeding rates will be affected.
Leukotriene B4 Driven Neutrophil Recruitment to the Skin Is Essential for Allergic Skin Inflammation
Authors: Michiko K. Oyoshi, Rui He, Yitang Li, Subhanjan Mondal, Juhan Yoon, Roshi Afshar, Mei Chen, David M. Lee, Hongbo Luo, Andrew D. Luster, John Cho, Lloyd Miller, Allison Larson, George Murphy, Raif Geha
Journal: Journal of Allergy and Clinical Immunology (2013)
Abstract 18895: Association of Type of Presentation, STEMI vs NSTEMI/UA, With the Relative Long-Term Incidence of Cardiovascular and Non-Cardiovascular Mortality
Authors: Alexander C Fanaroff, Ann Marie Navar, Robert Clare, Yuliya Lokhnygina, Matthew Roe, Robert Giugliano, Andrew Tershakovec, Michael Blazing
Journal: Circulation (2016)

Background: Understanding patient characteristics that may affect relative risk of cardiovascular (CV) versus non-CV death is important for designing clinical trials, since these characteristics di...
Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT
Authors: Gerbrig Berger, Leonie I. Kroeze, Theresia N. Koorenhof-Scheele, Aniek O. de Graaf, Kenichi Yoshida, Hiroo Ueno, Yuichi Shiraishi, Satoru Miyano, Eva van den Berg, Hein Schepers, Bert A. van der Reijden, Seishi Ogawa, Edo Vellenga, Joop H. Jansen
Journal: Blood (2018)
Women and kidney disease: reflections on World Kidney Day 2018
Authors: Giorgina B. Piccoli, Mona Alrukhaimi, Zhi-Hong Liu, Elena Zakharova, Adeera Levin, Philip Kam Tao Li, Guillermo Garcia-Garcia, Mohammed Benghanem-Gharbi, Kamyar Kalantar-Zadeh, Charles Kernahan, Latha Kumaraswami, Giorgina Barbara Piccoli, Gamal Saadi, Louise Fox, Elena Zakharova, Sharon Andreoli
Journal: Kidney International (2018)
Mumps Vaccine: Recommendation of the Public Health Service Advisory Committee on Immunization Practices
Journal: Annals of Internal Medicine (1978)

Diagnosis and Treatment1 June 1978Mumps Vaccine: Recommendation of the Public Health Service Advisory Committee on Immunization PracticesAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-88-6-819 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractThis statement from the Center for Disease Control very briefly summarizes the characteristics of mumps, and then describes live-mumps-virus vaccine, including adverse effects and immunity response. The use of the vaccine is reviewed, for dosage, in relation to age, and precautions and contraindications. Five bibliographic references are appended.Selected Bibliography1. HARRISTURNBULLISACSONKARZONWINKELSTEIN RCPDW: Mumps in a northeast metropolitan community. Am J Epidemiol 88:224-233, 1968 CrossrefMedlineGoogle Scholar2. HILLEMANBUYNAKWEIBELSTOKES MERJ: Live, attenuated mumps-virus vaccine. N Engl J Med 278:227-232, 1968 CrossrefMedlineGoogle Scholar3. MODLINORENSTEINBRANDLING-BENNETT FWA: Current status of mumps in the United States. J Infect Dis 132:106, 1975 CrossrefMedlineGoogle Scholar4. WEIBELBUYNAKMCLEANHILLEMAN REAM: Long-term follow-up for immunity after monovalent or combined live measles, mumps and rubella virus vaccines. Pediatrics 56:380-387, 1975 MedlineGoogle Scholar5. WITTEKARCHMER JA: Surveillance of mumps in the United States as background for use of vaccine. Public Health Rep 83:94-100, 1968 CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: ▸From the Center for Disease Control, U.S. Department of Health, Education, and Welfare; Atlanta, Georgia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byArthritis associated with common viral infections 1 June 1978Volume 88, Issue 6Page: 819-820KeywordsImmunityMedical servicesMorbidityMortalityMumpsVaccines Issue Published: 1 June 1978 Copyright & Permissions© 1978 American College of PhysiciansPDF downloadLoading ...